Genmab's transformation from a partner for drug developers to a company developing its own drugs has continued with a licensing deal for a Scancell cancer antibody.The Danish antibody specialist has exercised an option to license an anti-glycan monoclonal antibody generated using Scancell’s proprietary Glymab discovery platform – the second under an agreement between the two companies that dates back to 2022.The agreement includes an upfront payment and milestone payments tied to development, regulatory, and commercial milestones with the as-yet undisclosed drug candidate, plus royalties on sales, and has a total value of up to $630 million.

Genmab从药物开发商的合作伙伴转变为开发自己药物的公司，并继续签署Scancell癌症抗体的许可协议。丹麦抗体专家行使了使用Scancell专有的Glymab发现平台产生的抗聚糖单克隆抗体的许可权，这是两家公司于2022年签订的协议中的第二个。该协议包括与尚未公开的候选药物的开发，监管和商业里程碑相关的预付款和里程碑付款，以及销售版税，总价值高达6.3亿美元。

Shares in London-listed Scancell were up more than 8% following the announcement.Genmab took a worldwide license to another Scancell anti-glycan antibody – called SC129 – in October 2022 in a deal worth up to $624 million, and the company was an early investor in the UK biotech. SC129 targets sialyl-di-Lewis – thought to play a role in cancer progression and immune evasion – and is being investigated as a treatment for pancreatic cancer.The Glymab platform generates antibodies that target sugar motifs rather than proteins, which the company reckons offer differentiated properties, particularly as potential treatments for cancer as aberrant expression of glycans is often encountered on the surface of malignant cells.Scancell has a pipeline of five anti-glycan antibodies, with SC129 accompanied by fucosyl GM1-targeting SC134 for small cell lung cancer, Lewis-y-directed SC27 for epithelial cancers including gastric, colorectal and ovarian tumours, and SC2811 which targets a glycolipid on T cell stem cells.'This option exercise for another anti-glycan monoclonal antibody from the Glymab platform builds on our existing relationship with .

公告发布后，在伦敦上市的Scancell股价上涨了8%以上。2022年10月，Genmab以价值6.24亿美元的交易获得了另一种Scancell抗聚糖抗体SC129的全球许可证，该公司是英国生物技术公司的早期投资者。SC129靶向唾液酸二路易斯（被认为在癌症进展和免疫逃避中起作用），目前正在研究作为胰腺癌的治疗方法。Glymab平台产生靶向糖基序而非蛋白质的抗体，该公司认为这些抗体具有不同的特性，特别是作为癌症的潜在治疗方法，因为在恶性细胞表面经常会遇到聚糖的异常表达。Scancell拥有五种抗聚糖抗体的管道，其中SC129伴有针对小细胞肺癌的SC134的岩藻糖基GM1，针对包括胃癌，结直肠癌和卵巢肿瘤在内的上皮癌的Lewis-y定向SC27，以及针对T细胞干细胞糖脂的SC2811。”来自Glymab平台的另一种抗聚糖单克隆抗体的选择练习建立在我们与现有关系的基础上。